Gemcitabine and ionizing radiations: Radiosensitization or radio-chemotherapy combination;Gemcitabine et radiations ionisantes: Radiosensibilisation ou association radiochimiothérapique

Bulletin du Cancer

Volumn 89, Issue 4, 2002, Pages 369-379

  Azria, David ^a   Jacot, William ^a   Prost, Patricia ^a   Culine, Stéphane ^a   Ychou, Marc ^a   Lemanski, Claire ^a   Dubois, Jean Bernard ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Gemcitablne; Late side effects; Radiosensitization; Therapeutic ratio

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYADENOSINE TRIPHOSPHATE; GEMCITABINE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION SICKNESS; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SOLID TUMOR;

ADENOSINE TRIPHOSPHATE; CELL CYCLE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0036089040     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
2. Radiosensitizing nucleosides
3. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-bera-D-arabinofuranosylcytosine
4. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
5. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
6. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer
7. Gemcitabine: Current status of phase I and II trials
8. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
9. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
10. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
11. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
12. Induction of apoptosis by gemcitabine
13. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
14. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
15. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
16. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
17. Dependence of fiuorodeoxyuridine-mediated radiosensitization on S phase progression
18. Radiation enhancement of gemcitabine in three human cervical cancer cell lines
19. Activity of gemcitabine and its radiosensitization of human cervical cancer cells
20. Gemcitabine induced radiosensitization of human breast cancer cells
21. The effect of 2′-2′-difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
22. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
23. Radiosensitization of mouse sarcoma cells by fludatabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis
24. Combined effects of ionizing radiation and gemcitabine (GEM) in different cell lines
25. Enhancement of tumor radioresponse in vivo by gemcitabine
26. Maximizing therapeutic gain with gemcitabine and fractionated radiation
27. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
28. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
29. Measurement of DNA double-strand breaks in CHO cells at various stages of the cell cycle using pulsed field gel electrophoresis: Calibration by means of 125I decay
30. Gemzar (gemcitabine) with thoracic radiotherapy - A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
31. Phase I trial of radiation (RT) concurent with low-dose gemcitabine (GEM) for head and neck cancer: High mucosal and pharyngeal toxicity
32. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fiuorouracil plus weekly gemcitabine with concurent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity
33. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine
34. A phase I trial of radiation therapy (PT) plus concurent fixed dose amifostine (AMI) with escalating doses of twice-weekly gemcitabine (TW-GEM) in advanced pancreatic cancer
35. Radiation concurent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
36. Phase I study of gemcitabine combined with radiotherapy with or without amifostine in patients with locally advanced head and neck cancer
37. Phase I/II study of gemcitabine combined with cisplatin weekly and concurent thoracic MV-radiotherapy for patients with stage IIIA/B non small cell lung cancer (NSCLC)
38. A phase I study of gemcitabine and cisplatin with concurrent curative irradiation in stage III non-small cell lung cancer (NSCLC)
39. Gemcitabine with concurent 3d conformal radiation followed by consolidation gemcitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer (NSCLC)
40. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cispladn as induction therapy (Ind CT) and concomitant chemoradiothetapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB study 9431)
41. Phase I trial of gemcitabine (GEM) combined with Strontium-89 (Sr89) for treatment of painful bone metastases in androgen-independent prostate cancer (AIPCa)
42. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
43. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099
44. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
45. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells
46. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
47. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells
48. Biological basis for the interaction of chemotherapeutic agents and radiation therapy
49. Late complications of chemoradiotherapeutic combinations: Fundamental aspects and clinical experience
50. The Franz Buschke lecture: Late effects of chemotherapy and radiation therapy: A new hypothesis
51. A phase I study of simultaneous gemcitabine (GEM)/cisplatin (CDDP) and radiotherapy (RT) for patients (pts) with locally advanced pancreatic adenocarcinoma (PAC)
52. A phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer
53. A phase II study of gemcitabine combined with radiation therapy in patients with localized unresectable pancreatic cancer
54. Phase I study of gemcitabine (G) and escalating dose radiation therapy (RT) in patients with pancreatic carcinoma
55. Radiochemotherapy including gemcitabine and 5-fluorouracil for treatment of locally advanced pancreatic cancer
56. Chemoradiation therapy with gemcitabine (GEM) in advanced pancreatic cancer (APC)
57. Twice-weekly gemcitabine and concurent thoracic radiotherapy - A phase I/II study in patients with advanced non-small cell lung cancer
58. Concurent infusional gemcitabine and radiation in the treatment of advanced unresecrable GI malignancy
59. Phase I trial of concurent gemcitabine (GEM), infusional 5-fluorouracil (FU) and radiation therapy (RT) in patients with localized, unresectable pancreatic adenocarcinoma (PAC)
60. Phase I trial of gemcitabine (GEM) combined with radiation (XRT) for the treatment of locally advanced pancreatic adenocarcinoma
61. A phase I study of radiation therapy and gemcitabine in patients with locally advanced pancreatic carcinoma
62. A phase I study of gemcitabine in ombination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
63. Encouraging survival data ftom a phase I trial of radiation (RT) dose escalation with full dose gemcitabine (GEM) in patients with unresectable pancreatic cancer
64. Gemcitabine plus radiotherapy in stage II-III pancreatic cancer: A phase I trial
65. Phase I trial of gemcitabine, cisplatin (CDDP) and external beam radiation therapy (EBRT) for pancreatic cancer
66. Gemcitabine (G) in combination with radiationtherapy (R) in stage III-IV pancreatic cancer: First results of a current phase I study
67. Gemcitabine (G) in combination radiationtherapy (RT) in stage III-IV pancreatic cancer: First results of a current phase I study
68. Alternating/concomitant gemcitabine (GEM), cisplatin (CDDP) and radiotherapy (RT) in advanced squamous cell carcinoma of the head and neck (SCC-HN)
69. Low-dose gemcitabine with radiotherapy in advanced head and neck and thyroid tumors: A phase II study
70. Low-dose gemcitabine with radiotherapy in advanced head and neck and thyroid tumors: A phase II study
71. Phase I study of gemcitabine, 5-FU, and paclitaxel with RT in recurent or advanced head and neck cancer
72. Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC
73. Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study
74. Twice-weekly gemcitabine and concurrent thoracic radiotherapy - A phase I/II study in patients with advanced non-small cell lung cancer
75. Gemcitabine and radiation therapy for non-small cell lung cancer
76. Phase I study of gemcitabine (GEM)and high-dose thoracic radiation (RT) in stage III non-small cell lung cancer (NSCLC)
77. A phase Ib study of gemcitabine (GEM) and concurent radiotherapy (RT) in carcinoma of the cervix
78. Study of concurent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma
79. Pilot trial of concurent gemcitabine (GEM) and radiotherapy as a bladder preservation strategy